Amarin v. Hikma: Federal Circuit Reverses on Induced Infringement of Vascepa Patents
Amarin Pharma, Mochida Pharmaceutical, and Amarin Pharmaceuticals Ireland successfully appealed a dismissal of induced infringement claims against Hikma Pharmaceuticals over three patents protecting cardiovascular risk-reduction therapies. The Federal Circuit reversed in a 582-day appellate proceeding, holding that Amarin had plausibly pleaded induced infringement — reinstating claims that had been wiped out at the district court level.
Federal Circuit reinstates Amarin’s induced infringement claims against Hikma
Amarin Pharma, Inc., Mochida Pharmaceutical Co., Ltd., and Amarin Pharmaceuticals Ireland Limited jointly asserted three patents — US8642077B2, US9700537B2, and US10568861B1 — covering stable pharmaceutical compositions and methods of reducing cardiovascular event risk in high-risk patients. The accused product is Hikma Pharmaceuticals USA’s generic formulation competing with Vascepa, the flagship omega-3 drug developed by Amarin. The appeal was docketed at the Court of Appeals for the Federal Circuit on 22 November 2022.
The Federal Circuit closed the case on 25 June 2024 by reversing the lower court decision. The court held that Amarin had plausibly pleaded that Hikma induced infringement of the asserted patents — a finding that revives the infringement action and returns the dispute toward merits adjudication. A reversal at the Federal Circuit means the lower tribunal’s dismissal is nullified and the case is sent back for further proceedings consistent with the appellate ruling.
The 582-day duration reflects the complexity of pharmaceutical induced infringement analysis at the appellate level, where the court must assess whether label language and promotional conduct sufficiently encourage infringing use. What drove the reversal was likely the sufficiency of Amarin’s pleadings regarding Hikma’s labeling encouraging the precise cardiovascular indications covered by the patents. The specific district court proceedings to follow, and any eventual merits outcome on infringement or validity, remain outside the current public record.
Filing to Case Reversed in 582 days
582-day appellate proceeding — longer than the median Federal Circuit appeal
Federal Circuit reverses: what the ruling means for both parties
What ‘REVERSED’ means at Federal Circuit level
A Federal Circuit reversal nullifies the lower court’s decision entirely. Here, the district court had dismissed Amarin’s induced infringement claims — likely under Rule 12(b)(6) for failure to state a claim. The appellate court found that dismissal was error, holding that Amarin’s pleadings were legally sufficient to allege that Hikma’s conduct (including product labeling) plausibly encouraged physicians and patients to use the generic in the patented cardiovascular indications. The case now returns to the district court for further proceedings.
Dismissal overturned — case reinstatedAmarin’s claims survive: enforcement path reopened
The reversal is a significant procedural victory for Amarin, Mochida, and Amarin Pharmaceuticals Ireland. Claims under all three asserted patents — covering compositions and methods of reducing cardiovascular event risk — are reinstated at the district court level. Amarin now has the opportunity to pursue full merits adjudication, including discovery and trial. Commercially, the ruling preserves Vascepa’s IP perimeter against Hikma’s generic and signals that induced infringement based on labeling remains a viable enforcement theory.
Infringement claims reinstatedHikma loses its early dismissal shield
Hikma’s successful district court dismissal — which had extinguished all three patent claims without a merits ruling — has been vacated by the reversal. Hikma must now defend the induced infringement allegations on the merits, facing discovery, claim construction, and potentially trial. The Federal Circuit’s holding that Amarin’s pleadings were plausible raises the cost and risk profile of Hikma’s generic Vascepa commercialisation strategy considerably. The window for a low-cost early exit from this litigation has closed.
Early dismissal defence eliminatedPharma sector: induced infringement via labeling remains potent
This reversal reinforces that generic manufacturers cannot easily escape induced infringement claims at the pleading stage where product labeling tracks the patented therapeutic indication. For the cardiovascular pharmaceutical sector, it signals that Hatch-Waxman paragraph IV challenges may not neutralise all infringement exposure, particularly where the generic label encourages off-label or on-label use mirroring patented methods. Companies filing ANDAs on cardiovascular composition patents should audit label language carefully before launch.
Label-based inducement risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Amarin Pharma, Inc. | Company | Pharmaceutical patentee — holders of US8642077B2, US9700537B2, and US10568861B1 (Vascepa cardiovascular therapy)Search in Eureka ↗ |
| Co-Plaintiff | Mochida Pharmaceutical Co., Ltd. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Amarin Pharmaceuticals Ireland Limited | Individual | Search in Eureka ↗ |
| Defendant | Hikma Pharmaceuticals USA, Inc. | Company | Generic pharmaceutical manufacturer — Hikma Pharmaceuticals USA, Inc. and Hikma Pharmaceuticals PLCSearch in Eureka ↗ |
| Co-Defendant | Hikma Pharmaceuticals, PLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Nathan K. Kelley | Attorney | Counsel for Amarin Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nathanael D. Andrews | Attorney | Counsel for Amarin Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Perkins Coie LLP | Law Firm | Representing Amarin Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Alison Michelle King | Attorney | Counsel for Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Charles B. Klein | Attorney | Counsel for Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Claire A. Fundakowski | Attorney | Counsel for Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Eimeric ReigPlessis | Attorney | Counsel for Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Winston & Strawn, LLP | Law Firm | Representing Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s holding — that Amarin ‘plausibly pleaded’ induced infringement — is grounded in the Twombly/Iqbal pleading standard applied to patent cases. The court did not rule on whether infringement actually occurred; it held only that the complaint was legally sufficient to proceed. This distinction matters: Hikma retains its right to challenge infringement and validity on the merits at the district court. However, the reversal forecloses Hikma’s low-cost exit and signals that the appellate court viewed Hikma’s labeling conduct as raising a genuine question of inducement warranting full adjudication.
US8642077B2, US9700537B2, US10568861B1 — Vascepa cardiovascular risk-reduction patents
The three asserted patents — US8642077B2 (filed as US13/768906), US9700537B2 (filed as US15/431958), and US10568861B1 (filed as US16/599374) — form a layered protection portfolio covering Vascepa (icosapentaenoic acid / EPA). The patents protect distinct but overlapping aspects: stable pharmaceutical compositions preventing cardiovascular events in multi-risk patients, EPA-based methods of reducing cardiovascular event risk, and stable formulation technologies. Together they represent a prosecution strategy designed to maintain IP coverage across multiple patent families and filing dates.
Strategically, this three-patent bundle is characteristic of brand-name pharmaceutical IP practice: staggered expiry dates and overlapping claim scope make generic substitution legally complex even after any single patent expires or is invalidated. For the cardiovascular pharmaceutical sector, the Vascepa patent cluster is one of the most litigated omega-3 portfolios in the US, with Amarin having pursued enforcement against multiple ANDA filers. Any company developing or commercialising EPA-based cardiovascular formulations should treat all three patent families as active competitive threats requiring independent FTO clearance.
Should you run an FTO against US8642077B2, US9700537B2, and US10568861B1?
Any pharmaceutical company developing omega-3 or EPA-based cardiovascular formulations — or filing an ANDA referencing Vascepa — must assess freedom-to-operate against all three asserted patents. The Federal Circuit’s reversal confirms these patents remain enforceable and that induced infringement via product labeling is a plausible risk vector. R&D teams working on purified EPA compositions, stable lipid formulations, or cardiovascular risk-reduction methods should prioritise FTO clearance before IND filing, ANDA submission, or commercial launch.
PatSnap Eureka’s FTO Search Agent can map your product claims against the Vascepa patent cluster, identify prosecution history estoppel limits, flag continuation applications that may extend coverage, and surface prior art that could be used in IPR proceedings. Given that this litigation involves three related patent families with staggered filing dates, automated claim-by-claim comparison across the full Amarin/Mochida portfolio is essential for any realistic freedom-to-operate opinion in this therapeutic area.
Run a freedom-to-operate analysis on US8642077B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit induced infringement cases in pharmaceutical cardiovascular patents
Federal Circuit appeals involving induced infringement of pharmaceutical cardiovascular patents — including omega-3 and EPA-based formulation disputes — with comparable Hatch-Waxman ANDA contexts.
What this case signals for the cardiovascular pharmaceutical IP landscape
The Federal Circuit’s reversal in Amarin v. Hikma reshapes the risk calculus for generic pharma companies entering cardiovascular drug markets.
Generic label language is a live induced infringement risk — always
The Federal Circuit’s ruling confirms that product labeling directing physicians to patented cardiovascular indications can constitute plausible inducement. Generic manufacturers cannot assume that an abbreviated label or carve-out immunises them if the remaining label language still encourages the infringing method. Comprehensive label reviews prior to ANDA launch are non-negotiable in patent-dense therapeutic areas.
Pleading standards for induced infringement: the bar is lower than many expect
The court held Amarin’s pleadings were sufficient at the 12(b)(6) stage — meaning patent holders need not prove inducement at filing, only plead it plausibly. This is strategically important: brand-name pharma companies should not be discouraged from filing induced infringement claims by early motion practice from generics. The cost of surviving to discovery now falls on Hikma.
Amarin v Hikma — key questions answered
The Federal Circuit reversed the lower court dismissal, holding that Amarin, Mochida, and Amarin Pharmaceuticals Ireland had plausibly pleaded that Hikma induced infringement of three patents — US8642077B2, US9700537B2, and US10568861B1 — covering omega-3 cardiovascular compositions and methods. The reversal reinstates the infringement action for further proceedings at the district court.
Amarin and co-plaintiffs asserted US8642077B2, US9700537B2, and US10568861B1. These patents cover stable omega-3 (EPA) pharmaceutical compositions for preventing cardiovascular events in high-risk patients, methods of reducing cardiovascular event risk, and stable pharmaceutical formulation technologies — collectively forming the core Vascepa IP portfolio.
Induced infringement under 35 U.S.C. § 271(b) occurs when a party knowingly encourages another to directly infringe a patent. In pharmaceutical Hatch-Waxman cases, this typically arises when a generic manufacturer’s product label directs physicians or patients to use the drug in a manner that practises a patented method — such as the cardiovascular risk-reduction methods covered by Amarin’s patents.
Following the reversal, the case returns to the district court where Amarin’s induced infringement claims must be adjudicated on the merits. Hikma will have the opportunity to challenge infringement and patent validity, and the parties will proceed through discovery, claim construction, and potentially trial. The Federal Circuit’s ruling addressed only pleading sufficiency — not ultimate liability.
Amarin alleges that Hikma’s generic EPA formulation, through its product labeling, encourages physicians and patients to use the drug for the cardiovascular risk-reduction indications covered by the asserted patents. This theory — induced infringement via label language — was found plausible by the Federal Circuit, even though the district court had previously dismissed the claims. Merits adjudication will determine actual liability.
PatSnap Eureka searches patents and litigation data to answer instantly.